Company History
Corline® was founded in 1991 by three former employees at the very successful Swedish pharmaceuticals company Pharmacia (now part of Pfizer and GE), with the goal to commercialize an extra corporeal blood pump which at the time was an internal venture at Pharmacia.
Shortly after inauguration, the company shifted strategic focus from the blood pump system to the blood compatible surface technology, which had been one part of the original project, and develop and offer that as a stand-alone technology to other medical device manufacturers. And thus, the basic CHS™ technology platform and provider strategy was formed.
In 1997, Corline® started to supply a large stent manufacturer with CHS™ coated stents, and during 1997-2005 the company delivered more than 100,000 stents coated with CHS™.
In 2005, and as a result of research and development made by the company from year 2000 and onwards, another line of business was added to the company’s product offering - CHS™ applied to biological products and applications within Regenerative Medicine. Corline’s customers can now use CHS™ to immobilize heparin onto living cells and tissue, without compromising their viability. A truly unique product feature in the surface modification market!
Today, Corline® successfully offers its unique value proposition to large international customers within its two main segments: Medical Devices and Regenerative Medicine.
